Loading clinical trials...

Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer

Randomized Phase II Trial to Outline the Efficacy of Gemcitabine Containing Regimens (Gemcitabine/Carboplatin and Gemcitabine/Paclitaxel) When Used as Preoperative Chemotherapy In Patients With Stage I and II NSCLC

NCT00191256•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

To evaluate the rate of complete pathological response after 3 cycles of gemcitabine containing chemotherapy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically or cytologically confirmed non small cell lung cancer
•No prior chemotherapy or radiation for non small cell lung cancer
•No prior malignancy

Exclusion Criteria

•Pregnancy or breastfeeding
•Serious concomitant disorders

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Chapel Hill, North Carolina, United States

Key Dates

Start Date

June 1, 2001

Completion Date

July 1, 2006

Last Updated

January 26, 2007

Enrollment

Estimated participants

Conditions

Carcinoma, Non Small Cell Lung

Interventions

Gemcitabine

DRUG

Carboplatin

DRUG

Paclitaxel

DRUG

Locally Advanced NSCLC Hyperfractionated RT

NCT03128008

Carcinoma, Non Small Cell Lung (NSCLC)

View study

COMPLETEDPHASE2

Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

NCT01671332

Carcinoma, Non Small Cell Lung

View study

COMPLETEDPHASE2

Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer

NCT00798720

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 26, 2007Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer

Inclusion Criteria

Exclusion Criteria

Locally Advanced NSCLC Hyperfractionated RT

Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib